Global Complement Inhibitors Market Growth 2026-2032

January 2026 | 123 pages | ID: GE8FD292F355EN
LP Information

US$ 3,660.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Complement Inhibitors market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Complement inhibitors are a class of drugs designed to block the activation of the complement system, a key part of the immune response that, when overactivated, can cause tissue damage. These inhibitors target specific complement proteins to prevent the cascade of reactions that leads to inflammation and cell destruction. By controlling this process, complement inhibitors are used to treat a variety of complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica spectrum disorder (NMOSD), and geographic atrophy (GA) in age-related macular degeneration (AMD).

United States market for Complement Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Complement Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Complement Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Complement Inhibitors players cover CSL Behring, Takeda, Pharming Healthcare, Sanofi, Apellis Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the ?Complement Inhibitors Industry Forecast? looks at past sales and reviews total world Complement Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Complement Inhibitors sales for 2026 through 2032. With Complement Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Complement Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Complement Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Complement Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Complement Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Complement Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Complement Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of Complement Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
  • C1 Esterase Inhibitors
  • Complement C3 Inhibitors
  • Complement C5 Inhibitors
  • Complement Factor B Inhibitor
  • Complement Factor D Inhibitor
Segmentation by Application:
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Geographic Atrophy (GA)
  • Others
This report also splits the market by region:
  • Americas
    • United States
    • Canada
    • Mexico
    • Brazil
  • APAC
    • China
    • Japan
    • Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Middle East & Africa
    • Egypt
    • South Africa
    • Israel
    • Turkey
    • GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
  • CSL Behring
  • Takeda
  • Pharming Healthcare
  • Sanofi
  • Apellis Pharmaceuticals
  • UCB
  • Regeneron Pharmaceuticals
  • Astellas Pharma
  • Alexion Pharmaceuticals
  • Amgen
  • Roche
  • Novartis
  • Samsung Bioepis
Key Questions Addressed in this Report
What is the 10-year outlook for the global Complement Inhibitors market?
What factors are driving Complement Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Complement Inhibitors market opportunities vary by end market size?
How does Complement Inhibitors break out by Type, by Application?
1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Complement Inhibitors Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Complement Inhibitors by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Complement Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 Complement Inhibitors Segment by Type
  2.2.1 C1 Esterase Inhibitors
  2.2.2 Complement C3 Inhibitors
  2.2.3 Complement C5 Inhibitors
  2.2.4 Complement Factor B Inhibitor
  2.2.5 Complement Factor D Inhibitor
  2.2.6 Complement Inhibitors Sales by Type
    2.2.6.1 Global Complement Inhibitors Sales Market Share by Type (2021-2026)
    2.2.6.2 Global Complement Inhibitors Revenue and Market Share by Type (2021-2026)
    2.2.6.3 Global Complement Inhibitors Sale Price by Type (2021-2026)
2.3 Complement Inhibitors Segment by Application
  2.3.1 Paroxysmal Nocturnal Hemoglobinuria (PNH)
  2.3.2 Atypical Hemolytic Uremic Syndrome (aHUS)
  2.3.3 Geographic Atrophy (GA)
  2.3.4 Others
  2.3.5 Complement Inhibitors Sales by Application
    2.3.5.1 Global Complement Inhibitors Sale Market Share by Application (2021-2026)
    2.3.5.2 Global Complement Inhibitors Revenue and Market Share by Application (2021-2026)
    2.3.5.3 Global Complement Inhibitors Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Complement Inhibitors Breakdown Data by Company
  3.1.1 Global Complement Inhibitors Annual Sales by Company (2021-2026)
  3.1.2 Global Complement Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global Complement Inhibitors Annual Revenue by Company (2021-2026)
  3.2.1 Global Complement Inhibitors Revenue by Company (2021-2026)
  3.2.2 Global Complement Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global Complement Inhibitors Sale Price by Company
3.4 Key Manufacturers Complement Inhibitors Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Complement Inhibitors Product Location Distribution
  3.4.2 Players Complement Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR COMPLEMENT INHIBITORS BY GEOGRAPHIC REGION

4.1 World Historic Complement Inhibitors Market Size by Geographic Region (2021-2026)
  4.1.1 Global Complement Inhibitors Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global Complement Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Complement Inhibitors Market Size by Country/Region (2021-2026)
  4.2.1 Global Complement Inhibitors Annual Sales by Country/Region (2021-2026)
  4.2.2 Global Complement Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Complement Inhibitors Sales Growth
4.4 APAC Complement Inhibitors Sales Growth
4.5 Europe Complement Inhibitors Sales Growth
4.6 Middle East & Africa Complement Inhibitors Sales Growth

5 AMERICAS

5.1 Americas Complement Inhibitors Sales by Country
  5.1.1 Americas Complement Inhibitors Sales by Country (2021-2026)
  5.1.2 Americas Complement Inhibitors Revenue by Country (2021-2026)
5.2 Americas Complement Inhibitors Sales by Type (2021-2026)
5.3 Americas Complement Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Complement Inhibitors Sales by Region
  6.1.1 APAC Complement Inhibitors Sales by Region (2021-2026)
  6.1.2 APAC Complement Inhibitors Revenue by Region (2021-2026)
6.2 APAC Complement Inhibitors Sales by Type (2021-2026)
6.3 APAC Complement Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Complement Inhibitors by Country
  7.1.1 Europe Complement Inhibitors Sales by Country (2021-2026)
  7.1.2 Europe Complement Inhibitors Revenue by Country (2021-2026)
7.2 Europe Complement Inhibitors Sales by Type (2021-2026)
7.3 Europe Complement Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Complement Inhibitors by Country
  8.1.1 Middle East & Africa Complement Inhibitors Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Complement Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa Complement Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa Complement Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Complement Inhibitors
10.3 Manufacturing Process Analysis of Complement Inhibitors
10.4 Industry Chain Structure of Complement Inhibitors

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Complement Inhibitors Distributors
11.3 Complement Inhibitors Customer

12 WORLD FORECAST REVIEW FOR COMPLEMENT INHIBITORS BY GEOGRAPHIC REGION

12.1 Global Complement Inhibitors Market Size Forecast by Region
  12.1.1 Global Complement Inhibitors Forecast by Region (2027-2032)
  12.1.2 Global Complement Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Complement Inhibitors Forecast by Type (2027-2032)
12.7 Global Complement Inhibitors Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 CSL Behring
  13.1.1 CSL Behring Company Information
  13.1.2 CSL Behring Complement Inhibitors Product Portfolios and Specifications
  13.1.3 CSL Behring Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 CSL Behring Main Business Overview
  13.1.5 CSL Behring Latest Developments
13.2 Takeda
  13.2.1 Takeda Company Information
  13.2.2 Takeda Complement Inhibitors Product Portfolios and Specifications
  13.2.3 Takeda Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 Takeda Main Business Overview
  13.2.5 Takeda Latest Developments
13.3 Pharming Healthcare
  13.3.1 Pharming Healthcare Company Information
  13.3.2 Pharming Healthcare Complement Inhibitors Product Portfolios and Specifications
  13.3.3 Pharming Healthcare Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.3.4 Pharming Healthcare Main Business Overview
  13.3.5 Pharming Healthcare Latest Developments
13.4 Sanofi
  13.4.1 Sanofi Company Information
  13.4.2 Sanofi Complement Inhibitors Product Portfolios and Specifications
  13.4.3 Sanofi Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.4.4 Sanofi Main Business Overview
  13.4.5 Sanofi Latest Developments
13.5 Apellis Pharmaceuticals
  13.5.1 Apellis Pharmaceuticals Company Information
  13.5.2 Apellis Pharmaceuticals Complement Inhibitors Product Portfolios and Specifications
  13.5.3 Apellis Pharmaceuticals Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.5.4 Apellis Pharmaceuticals Main Business Overview
  13.5.5 Apellis Pharmaceuticals Latest Developments
13.6 UCB
  13.6.1 UCB Company Information
  13.6.2 UCB Complement Inhibitors Product Portfolios and Specifications
  13.6.3 UCB Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.6.4 UCB Main Business Overview
  13.6.5 UCB Latest Developments
13.7 Regeneron Pharmaceuticals
  13.7.1 Regeneron Pharmaceuticals Company Information
  13.7.2 Regeneron Pharmaceuticals Complement Inhibitors Product Portfolios and Specifications
  13.7.3 Regeneron Pharmaceuticals Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.7.4 Regeneron Pharmaceuticals Main Business Overview
  13.7.5 Regeneron Pharmaceuticals Latest Developments
13.8 Astellas Pharma
  13.8.1 Astellas Pharma Company Information
  13.8.2 Astellas Pharma Complement Inhibitors Product Portfolios and Specifications
  13.8.3 Astellas Pharma Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.8.4 Astellas Pharma Main Business Overview
  13.8.5 Astellas Pharma Latest Developments
13.9 Alexion Pharmaceuticals
  13.9.1 Alexion Pharmaceuticals Company Information
  13.9.2 Alexion Pharmaceuticals Complement Inhibitors Product Portfolios and Specifications
  13.9.3 Alexion Pharmaceuticals Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.9.4 Alexion Pharmaceuticals Main Business Overview
  13.9.5 Alexion Pharmaceuticals Latest Developments
13.10 Amgen
  13.10.1 Amgen Company Information
  13.10.2 Amgen Complement Inhibitors Product Portfolios and Specifications
  13.10.3 Amgen Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.10.4 Amgen Main Business Overview
  13.10.5 Amgen Latest Developments
13.11 Roche
  13.11.1 Roche Company Information
  13.11.2 Roche Complement Inhibitors Product Portfolios and Specifications
  13.11.3 Roche Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.11.4 Roche Main Business Overview
  13.11.5 Roche Latest Developments
13.12 Novartis
  13.12.1 Novartis Company Information
  13.12.2 Novartis Complement Inhibitors Product Portfolios and Specifications
  13.12.3 Novartis Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.12.4 Novartis Main Business Overview
  13.12.5 Novartis Latest Developments
13.13 Samsung Bioepis
  13.13.1 Samsung Bioepis Company Information
  13.13.2 Samsung Bioepis Complement Inhibitors Product Portfolios and Specifications
  13.13.3 Samsung Bioepis Complement Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  13.13.4 Samsung Bioepis Main Business Overview
  13.13.5 Samsung Bioepis Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Complement Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Complement Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of C1 Esterase Inhibitors
Table 4. Major Players of Complement C3 Inhibitors
Table 5. Major Players of Complement C5 Inhibitors
Table 6. Major Players of Complement Factor B Inhibitor
Table 7. Major Players of Complement Factor D Inhibitor
Table 8. Global Complement Inhibitors Sales by Type (2021-2026) & (K Units)
Table 9. Global Complement Inhibitors Sales Market Share by Type (2021-2026)
Table 10. Global Complement Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 11. Global Complement Inhibitors Revenue Market Share by Type (2021-2026)
Table 12. Global Complement Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Complement Inhibitors Sale by Application (2021-2026) & (K Units)
Table 14. Global Complement Inhibitors Sale Market Share by Application (2021-2026)
Table 15. Global Complement Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 16. Global Complement Inhibitors Revenue Market Share by Application (2021-2026)
Table 17. Global Complement Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global Complement Inhibitors Sales by Company (2021-2026) & (K Units)
Table 19. Global Complement Inhibitors Sales Market Share by Company (2021-2026)
Table 20. Global Complement Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 21. Global Complement Inhibitors Revenue Market Share by Company (2021-2026)
Table 22. Global Complement Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers Complement Inhibitors Producing Area Distribution and Sales Area
Table 24. Players Complement Inhibitors Products Offered
Table 25. Complement Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Complement Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global Complement Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 30. Global Complement Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global Complement Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global Complement Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global Complement Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 34. Global Complement Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Complement Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Complement Inhibitors Sales by Country (2021-2026) & (K Units)
Table 37. Americas Complement Inhibitors Sales Market Share by Country (2021-2026)
Table 38. Americas Complement Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas Complement Inhibitors Sales by Type (2021-2026) & (K Units)
Table 40. Americas Complement Inhibitors Sales by Application (2021-2026) & (K Units)
Table 41. APAC Complement Inhibitors Sales by Region (2021-2026) & (K Units)
Table 42. APAC Complement Inhibitors Sales Market Share by Region (2021-2026)
Table 43. APAC Complement Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC Complement Inhibitors Sales by Type (2021-2026) & (K Units)
Table 45. APAC Complement Inhibitors Sales by Application (2021-2026) & (K Units)
Table 46. Europe Complement Inhibitors Sales by Country (2021-2026) & (K Units)
Table 47. Europe Complement Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe Complement Inhibitors Sales by Type (2021-2026) & (K Units)
Table 49. Europe Complement Inhibitors Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa Complement Inhibitors Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa Complement Inhibitors Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa Complement Inhibitors Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa Complement Inhibitors Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Complement Inhibitors
Table 55. Key Market Challenges & Risks of Complement Inhibitors
Table 56. Key Industry Trends of Complement Inhibitors
Table 57. Complement Inhibitors Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Complement Inhibitors Distributors List
Table 60. Complement Inhibitors Customer List
Table 61. Global Complement Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global Complement Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas Complement Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas Complement Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC Complement Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC Complement Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe Complement Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe Complement Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa Complement Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa Complement Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global Complement Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global Complement Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Complement Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global Complement Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. CSL Behring Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 76. CSL Behring Complement Inhibitors Product Portfolios and Specifications
Table 77. CSL Behring Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. CSL Behring Main Business
Table 79. CSL Behring Latest Developments
Table 80. Takeda Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 81. Takeda Complement Inhibitors Product Portfolios and Specifications
Table 82. Takeda Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Takeda Main Business
Table 84. Takeda Latest Developments
Table 85. Pharming Healthcare Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 86. Pharming Healthcare Complement Inhibitors Product Portfolios and Specifications
Table 87. Pharming Healthcare Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. Pharming Healthcare Main Business
Table 89. Pharming Healthcare Latest Developments
Table 90. Sanofi Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 91. Sanofi Complement Inhibitors Product Portfolios and Specifications
Table 92. Sanofi Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Sanofi Main Business
Table 94. Sanofi Latest Developments
Table 95. Apellis Pharmaceuticals Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 96. Apellis Pharmaceuticals Complement Inhibitors Product Portfolios and Specifications
Table 97. Apellis Pharmaceuticals Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Apellis Pharmaceuticals Main Business
Table 99. Apellis Pharmaceuticals Latest Developments
Table 100. UCB Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 101. UCB Complement Inhibitors Product Portfolios and Specifications
Table 102. UCB Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. UCB Main Business
Table 104. UCB Latest Developments
Table 105. Regeneron Pharmaceuticals Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 106. Regeneron Pharmaceuticals Complement Inhibitors Product Portfolios and Specifications
Table 107. Regeneron Pharmaceuticals Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Regeneron Pharmaceuticals Main Business
Table 109. Regeneron Pharmaceuticals Latest Developments
Table 110. Astellas Pharma Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 111. Astellas Pharma Complement Inhibitors Product Portfolios and Specifications
Table 112. Astellas Pharma Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. Astellas Pharma Main Business
Table 114. Astellas Pharma Latest Developments
Table 115. Alexion Pharmaceuticals Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 116. Alexion Pharmaceuticals Complement Inhibitors Product Portfolios and Specifications
Table 117. Alexion Pharmaceuticals Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. Alexion Pharmaceuticals Main Business
Table 119. Alexion Pharmaceuticals Latest Developments
Table 120. Amgen Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 121. Amgen Complement Inhibitors Product Portfolios and Specifications
Table 122. Amgen Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. Amgen Main Business
Table 124. Amgen Latest Developments
Table 125. Roche Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 126. Roche Complement Inhibitors Product Portfolios and Specifications
Table 127. Roche Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. Roche Main Business
Table 129. Roche Latest Developments
Table 130. Novartis Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 131. Novartis Complement Inhibitors Product Portfolios and Specifications
Table 132. Novartis Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 133. Novartis Main Business
Table 134. Novartis Latest Developments
Table 135. Samsung Bioepis Basic Information, Complement Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 136. Samsung Bioepis Complement Inhibitors Product Portfolios and Specifications
Table 137. Samsung Bioepis Complement Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 138. Samsung Bioepis Main Business
Table 139. Samsung Bioepis Latest Developments

LIST OF FIGURES

Figure 1. Picture of Complement Inhibitors
Figure 2. Complement Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Complement Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Complement Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Complement Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Complement Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. Complement Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of C1 Esterase Inhibitors
Figure 12. Product Picture of Complement C3 Inhibitors
Figure 13. Product Picture of Complement C5 Inhibitors
Figure 14. Product Picture of Complement Factor B Inhibitor
Figure 15. Product Picture of Complement Factor D Inhibitor
Figure 16. Global Complement Inhibitors Sales Market Share by Type in 2026
Figure 17. Global Complement Inhibitors Revenue Market Share by Type (2021-2026)
Figure 18. Complement Inhibitors Consumed in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Figure 19. Global Complement Inhibitors Market: Paroxysmal Nocturnal Hemoglobinuria (PNH) (2021-2026) & (K Units)
Figure 20. Complement Inhibitors Consumed in Atypical Hemolytic Uremic Syndrome (aHUS)
Figure 21. Global Complement Inhibitors Market: Atypical Hemolytic Uremic Syndrome (aHUS) (2021-2026) & (K Units)
Figure 22. Complement Inhibitors Consumed in Geographic Atrophy (GA)
Figure 23. Global Complement Inhibitors Market: Geographic Atrophy (GA) (2021-2026) & (K Units)
Figure 24. Complement Inhibitors Consumed in Others
Figure 25. Global Complement Inhibitors Market: Others (2021-2026) & (K Units)
Figure 26. Global Complement Inhibitors Sale Market Share by Application (2025)
Figure 27. Global Complement Inhibitors Revenue Market Share by Application in 2026
Figure 28. Complement Inhibitors Sales by Company in 2026 (K Units)
Figure 29. Global Complement Inhibitors Sales Market Share by Company in 2026
Figure 30. Complement Inhibitors Revenue by Company in 2026 ($ millions)
Figure 31. Global Complement Inhibitors Revenue Market Share by Company in 2026
Figure 32. Global Complement Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 33. Global Complement Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 34. Americas Complement Inhibitors Sales 2021-2026 (K Units)
Figure 35. Americas Complement Inhibitors Revenue 2021-2026 ($ millions)
Figure 36. APAC Complement Inhibitors Sales 2021-2026 (K Units)
Figure 37. APAC Complement Inhibitors Revenue 2021-2026 ($ millions)
Figure 38. Europe Complement Inhibitors Sales 2021-2026 (K Units)
Figure 39. Europe Complement Inhibitors Revenue 2021-2026 ($ millions)
Figure 40. Middle East & Africa Complement Inhibitors Sales 2021-2026 (K Units)
Figure 41. Middle East & Africa Complement Inhibitors Revenue 2021-2026 ($ millions)
Figure 42. Americas Complement Inhibitors Sales Market Share by Country in 2026
Figure 43. Americas Complement Inhibitors Revenue Market Share by Country (2021-2026)
Figure 44. Americas Complement Inhibitors Sales Market Share by Type (2021-2026)
Figure 45. Americas Complement Inhibitors Sales Market Share by Application (2021-2026)
Figure 46. United States Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 47. Canada Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 48. Mexico Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 49. Brazil Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 50. APAC Complement Inhibitors Sales Market Share by Region in 2026
Figure 51. APAC Complement Inhibitors Revenue Market Share by Region (2021-2026)
Figure 52. APAC Complement Inhibitors Sales Market Share by Type (2021-2026)
Figure 53. APAC Complement Inhibitors Sales Market Share by Application (2021-2026)
Figure 54. China Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 55. Japan Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 56. South Korea Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 57. Southeast Asia Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 58. India Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 59. Australia Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 60. China Taiwan Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 61. Europe Complement Inhibitors Sales Market Share by Country in 2026
Figure 62. Europe Complement Inhibitors Revenue Market Share by Country (2021-2026)
Figure 63. Europe Complement Inhibitors Sales Market Share by Type (2021-2026)
Figure 64. Europe Complement Inhibitors Sales Market Share by Application (2021-2026)
Figure 65. Germany Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 66. France Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 67. UK Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 68. Italy Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 69. Russia Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 70. Middle East & Africa Complement Inhibitors Sales Market Share by Country (2021-2026)
Figure 71. Middle East & Africa Complement Inhibitors Sales Market Share by Type (2021-2026)
Figure 72. Middle East & Africa Complement Inhibitors Sales Market Share by Application (2021-2026)
Figure 73. Egypt Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 74. South Africa Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 75. Israel Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 76. Turkey Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 77. GCC Countries Complement Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of Complement Inhibitors in 2026
Figure 79. Manufacturing Process Analysis of Complement Inhibitors
Figure 80. Industry Chain Structure of Complement Inhibitors
Figure 81. Channels of Distribution
Figure 82. Global Complement Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 83. Global Complement Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 84. Global Complement Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 85. Global Complement Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 86. Global Complement Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 87. Global Complement Inhibitors Revenue Market Share Forecast by Application (2027-2032)